Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Daniel E. Morganstern"'
Autor:
Mary-Ellen Taplin, Glenn J. Bubley, Barur Rajeshkumar, Todd Shuster, Yoo-Joung Ko, Daniel E. Morganstern
Publikováno v:
Seminars in Oncology. 28:32-39
Autor:
Philip W. Kantoff, W. V. Walsh, Mary-Ellen Taplin, Marc S. Ernstoff, Glenn J. Bubley, Geoffrey Buckle, Daniel E. Morganstern, Wanling Xie, Mari Nakabayashi
Publikováno v:
Urology. 81(3)
To evaluate long-term follow-up of a phase II trial of chemohormonal therapy in 62 men with prostate cancer biochemical relapse (BR).Treatment was 4 cycles of docetaxel (70 mg/m(2)) every 3 weeks and estramustine 280 mg three times a day (days 1-5) f
Autor:
Daniel E. Morganstern, Wanling Xie, Glenn J. Bubley, Mary-Ellen Taplin, Marc S. Ernstoff, Meredith M. Regan, W. V. Walsh
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 24(34)
Purpose Androgen-deprivation therapy (ADT) is effective for relapsed prostate cancer, but is rarely curative. The purpose of this trial was to determine the feasibility, toxicity, and prostate-specific antigen (PSA) response of chemotherapy and limit
Autor:
Glenn J. Bubley, Yoo-Joung Ko, Todd D. Shuster, Daniel E. Morganstern, Barur R. Rajeshkumar, Mary-Ellen Taplin
Publikováno v:
Seminars in oncology. 28(4 Suppl 15)
Over the past 10 years, men with prostate cancer have received earlier diagnoses and are undergoing prostatectomy and/or radiation therapy with curative intent; however, many men have increasing prostate-specific antigen (PSA) levels without evidence
Autor:
Glenn J. Bubley, Daniel E. Morganstern, Isabella Mosberger, Jing Pan, Martin Susani, Andreas Chott, Melissa P. Upton, Zijie Sun, Tong Li, Steven P. Balk
An important biological feature of prostate cancer (PCa) is its marked preference for bone marrow as a metastatic site. To identify factors that may support the growth of PCa in bone marrow, expression of receptor and nonreceptor tyrosine kinases by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6744fb67130bcca5b0be7da126fb194
https://europepmc.org/articles/PMC1867033/
https://europepmc.org/articles/PMC1867033/
Autor:
Glenn J. Bubley, Philip W. Kantoff, Meredith M. Regan, Mary-Ellen Taplin, Daniel E. Morganstern, Wanling Xie, Geoffrey Buckle, Mari Nakabayashi, Marc S. Ernstoff, W. V. Walsh
Publikováno v:
Journal of Clinical Oncology. 29:4657-4657
4657 Background: Treatment options for prostate cancer (PCa) patients with biochemical relapse (BR) after local therapy include surveillance, salvage local therapy, androgen deprivation therapy (AD...
Autor:
Daniel E. Morganstern, Wanling Xie, Meredith M. Regan, Marc S. Ernstoff, Mary-Ellen Taplin, Glenn J. Bubley
Publikováno v:
Journal of Clinical Oncology. 24:4559-4559
4559 Background: Androgen deprivation therapy (ADT) is effective for relapsed prostate cancer, but is rarely curative. The purpose of this trial was to determine the feasibility, toxicity and PSA response of chemotherapy and ADT for men with PSA rela
Publikováno v:
Journal of Genetic Counseling; Jun2019, Vol. 28 Issue 3, p708-716, 9p
Autor:
Lichtman SM; Stuart M. Lichtman and Maria Theodoulou, Memorial Sloan Kettering Cancer Center, New York, NY; Constance T. Cirrincione, Duke University; Harvey Jay Cohen, Duke University Medical Center, Durham; Gustave Magrinat, Cone Health Cancer Center, Greensboro; Hyman B. Muss, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Arti Hurria, City of Hope, Duarte, CA; Aminah Jatoi, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD; Julie Gralow, Seattle Cancer Care Alliance, Seattle, WA; and Daniel E. Morganstern, Dana-Farber Cancer Institute, Boston, MA. lichtmas@mskcc.org., Cirrincione CT; Stuart M. Lichtman and Maria Theodoulou, Memorial Sloan Kettering Cancer Center, New York, NY; Constance T. Cirrincione, Duke University; Harvey Jay Cohen, Duke University Medical Center, Durham; Gustave Magrinat, Cone Health Cancer Center, Greensboro; Hyman B. Muss, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Arti Hurria, City of Hope, Duarte, CA; Aminah Jatoi, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD; Julie Gralow, Seattle Cancer Care Alliance, Seattle, WA; and Daniel E. Morganstern, Dana-Farber Cancer Institute, Boston, MA., Hurria A; Stuart M. Lichtman and Maria Theodoulou, Memorial Sloan Kettering Cancer Center, New York, NY; Constance T. Cirrincione, Duke University; Harvey Jay Cohen, Duke University Medical Center, Durham; Gustave Magrinat, Cone Health Cancer Center, Greensboro; Hyman B. Muss, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Arti Hurria, City of Hope, Duarte, CA; Aminah Jatoi, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD; Julie Gralow, Seattle Cancer Care Alliance, Seattle, WA; and Daniel E. Morganstern, Dana-Farber Cancer Institute, Boston, MA., Jatoi A; Stuart M. Lichtman and Maria Theodoulou, Memorial Sloan Kettering Cancer Center, New York, NY; Constance T. Cirrincione, Duke University; Harvey Jay Cohen, Duke University Medical Center, Durham; Gustave Magrinat, Cone Health Cancer Center, Greensboro; Hyman B. Muss, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Arti Hurria, City of Hope, Duarte, CA; Aminah Jatoi, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD; Julie Gralow, Seattle Cancer Care Alliance, Seattle, WA; and Daniel E. Morganstern, Dana-Farber Cancer Institute, Boston, MA., Theodoulou M; Stuart M. Lichtman and Maria Theodoulou, Memorial Sloan Kettering Cancer Center, New York, NY; Constance T. Cirrincione, Duke University; Harvey Jay Cohen, Duke University Medical Center, Durham; Gustave Magrinat, Cone Health Cancer Center, Greensboro; Hyman B. Muss, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Arti Hurria, City of Hope, Duarte, CA; Aminah Jatoi, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD; Julie Gralow, Seattle Cancer Care Alliance, Seattle, WA; and Daniel E. Morganstern, Dana-Farber Cancer Institute, Boston, MA., Wolff AC; Stuart M. Lichtman and Maria Theodoulou, Memorial Sloan Kettering Cancer Center, New York, NY; Constance T. Cirrincione, Duke University; Harvey Jay Cohen, Duke University Medical Center, Durham; Gustave Magrinat, Cone Health Cancer Center, Greensboro; Hyman B. Muss, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Arti Hurria, City of Hope, Duarte, CA; Aminah Jatoi, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD; Julie Gralow, Seattle Cancer Care Alliance, Seattle, WA; and Daniel E. Morganstern, Dana-Farber Cancer Institute, Boston, MA., Gralow J; Stuart M. Lichtman and Maria Theodoulou, Memorial Sloan Kettering Cancer Center, New York, NY; Constance T. Cirrincione, Duke University; Harvey Jay Cohen, Duke University Medical Center, Durham; Gustave Magrinat, Cone Health Cancer Center, Greensboro; Hyman B. Muss, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Arti Hurria, City of Hope, Duarte, CA; Aminah Jatoi, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD; Julie Gralow, Seattle Cancer Care Alliance, Seattle, WA; and Daniel E. Morganstern, Dana-Farber Cancer Institute, Boston, MA., Morganstern DE; Stuart M. Lichtman and Maria Theodoulou, Memorial Sloan Kettering Cancer Center, New York, NY; Constance T. Cirrincione, Duke University; Harvey Jay Cohen, Duke University Medical Center, Durham; Gustave Magrinat, Cone Health Cancer Center, Greensboro; Hyman B. Muss, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Arti Hurria, City of Hope, Duarte, CA; Aminah Jatoi, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD; Julie Gralow, Seattle Cancer Care Alliance, Seattle, WA; and Daniel E. Morganstern, Dana-Farber Cancer Institute, Boston, MA., Magrinat G; Stuart M. Lichtman and Maria Theodoulou, Memorial Sloan Kettering Cancer Center, New York, NY; Constance T. Cirrincione, Duke University; Harvey Jay Cohen, Duke University Medical Center, Durham; Gustave Magrinat, Cone Health Cancer Center, Greensboro; Hyman B. Muss, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Arti Hurria, City of Hope, Duarte, CA; Aminah Jatoi, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD; Julie Gralow, Seattle Cancer Care Alliance, Seattle, WA; and Daniel E. Morganstern, Dana-Farber Cancer Institute, Boston, MA., Cohen HJ; Stuart M. Lichtman and Maria Theodoulou, Memorial Sloan Kettering Cancer Center, New York, NY; Constance T. Cirrincione, Duke University; Harvey Jay Cohen, Duke University Medical Center, Durham; Gustave Magrinat, Cone Health Cancer Center, Greensboro; Hyman B. Muss, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Arti Hurria, City of Hope, Duarte, CA; Aminah Jatoi, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD; Julie Gralow, Seattle Cancer Care Alliance, Seattle, WA; and Daniel E. Morganstern, Dana-Farber Cancer Institute, Boston, MA., Muss HB; Stuart M. Lichtman and Maria Theodoulou, Memorial Sloan Kettering Cancer Center, New York, NY; Constance T. Cirrincione, Duke University; Harvey Jay Cohen, Duke University Medical Center, Durham; Gustave Magrinat, Cone Health Cancer Center, Greensboro; Hyman B. Muss, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Arti Hurria, City of Hope, Duarte, CA; Aminah Jatoi, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD; Julie Gralow, Seattle Cancer Care Alliance, Seattle, WA; and Daniel E. Morganstern, Dana-Farber Cancer Institute, Boston, MA.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2016 Mar 01; Vol. 34 (7), pp. 699-705. Date of Electronic Publication: 2016 Jan 11.